Reinhart

Monica Mark Discusses Patent Strategy Following Amgen vs Sanofi Patent Dispute

Reinhart shareholder Monica Mark was quoted in *Nature Biotechnology*, a leading, peer-reviewed scientific journal. In the article, which covers the Supreme Court of the United States decision in *Amgen, Inc. v. Sanofi*, Monica highlights a potential shift in patent strategy relating to invalidity challenges.

Monica is member of Reinhart's Litigation and Intellectual Property practices, focusing on intellectual property disputes and appellate matters while helping clients successfully navigate volatile or complex legal proceedings. Advising on patent cases from the filing of the complaint through claim construction, summary judgment and trial, she has substantial experience in trademark, trade dress and copyright litigation.

Monica recently authored a detailed client alert examining the *Amgen* case and the enablement requirement of the Patent Act.

POSTED:

Aug 13, 2023

RELATED PRACTICES:

Intellectual Property
https://www.reinhartlaw.com/practices/intellectual-property

RELATED SERVICES:

Patent and Intellectual Property Litigation
https://www.reinhartlaw.com/services/patent-and-intellectual-property-litigation

RELATED PEOPLE:

Monica A. Mark
https://www.reinhartlaw.com/people/monica-mark

These materials provide general information which does not constitute legal or tax advice and should not be relied upon as such. Particular facts or future developments in the law may affect the topic(s) addressed within these materials. Always consult with a lawyer about your particular circumstances before acting on any information presented in these materials because it may not be applicable to you or your situation. Providing these materials to you does not create an attorney/client relationship. You should not provide confidential information to us until Reinhart agrees to represent you.

All materials copyright © 2025 Reinhart Boerner Van Deuren S.C. All rights reserved.